No title
Background: Asthma with low levels of type 2 (T2) biomarkers is poorly understood. Objective: To characterize severe asthma phenotypes and compare changes in asthma outcomes from pre- to postbiologic treatment along a gradient of T2 involvement. Methods: This was a registry-based cohort study including data from 24 countries. Biomarker distribution (blood eosinophil count, fractional exhaled nitri
